ptvg-hp plasmid dna vaccine
Vaccineexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2011 (NCT01341652)
Timeline
Indications
Mechanism of action
- Prostatic acid phosphataseImmunity, active
ACP3 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ptvg-hp plasmid dna vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07090148 | Phase 1 | Dec 31, 2025 | Department of Defense, University of Wisconsin |
| NCT02499835 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2015 | National Cancer Institute (NCI), University of Wisconsin |
| NCT01341652 | Phase 2 | Apr 1, 2011 | University of Wisconsin |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Wisconsin | Academic/Hospital | 3 | 3 | 2 | 2011 |
| Department of Defense | Government | 1 | 0 | 1 | 2025 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1